Dihydroergoline Mesylate Injection

Animal tests have shown that this product can change central nervous system signal transmission, and there is evidence that it has an agonist effect on dopamine receptors and 5-hydroxytryptamine receptors; and a blocking effect on α-adrenergic receptors. It can improve damaged brain metabolic function, which reflects changes in brain electrical activity, especially the EEG spectrum. The beneficial effect on the EEG has been confirmed by human trials. This product can also shorten cerebral circulation time. Controlled clinical trials have shown that this product can improve intellectual decline, especially many symptoms of age-related intellectual decline, such as self-care, social behavior, emotional state and intellectual behavior. This product has the effect of stabilizing cerebral vascular tension, which is why it has a preventive effect on migraine.

Dihydroergoceptin mesylate is composed of equal proportions of dihydroergocornine mesylate, dihydroergocryptine mesylate (there are two isomers, dihydro-α-ergocryptine mesylate and dihydro-β-ergocryptine mesylate, in a ratio of 2:1) and dihydroergoline mesylate.

This product is white or off-white loose mass or powder.

It is used as an adjunct to the treatment of intellectual, emotional, physical and behavioral disturbances in patients with mild brain damage caused by central nervous system, metabolic or arteriosclerosis. Such disturbances may cause dizziness, inattention, disorientation, memory impairment, lack of initiative, emotional depression, social incompetence, and difficulty in daily life and self-care. Cerebrovascular disease.

0.3 mg (1 vial) each time, dissolved in 5% glucose injection or 20 ml of normal saline and slowly injected intravenously, or dissolved in 5% glucose or 250 ml of normal saline and intravenously dripped once or twice a day. Intramuscular or subcutaneous injection: 0.3 mg (1 vial) each time, dissolved in normal saline and injected twice a day.

15-20% of patients experience nasal congestion, headache, transient nausea and stomach discomfort, but these can usually be avoided when taken with food. In most cases, no special treatment is required and the side effects will disappear naturally. The following adverse reactions may also occur: vomiting, diarrhea, skin reactions, paresthesia, and aggravated angina. At the same time, arrhythmias and bradycardia, peripheral arterial vascular disorders (such as limb ischemia) are occasionally seen. In individual cases, changes (fibrosis) in connective tissue may occur after taking high doses (compared to the recommended dose) of this product for a long period of time (several years). These changes can also involve the retroperitoneum and are accompanied by symptoms such as back pain or lower urinary tract obstruction.

It is contraindicated for patients who are known to be allergic to any of the ingredients in this product, patients with vascular diseases (history of cerebrovascular disease, Raynaud’s phenomenon), patients with temporary arteritis, patients with coronary heart disease (angina pectoris, silent ischemia, etc.), patients with severe liver damage and patients with sepsis. It is contraindicated for pregnant and lactating women.

This product can enhance the effects of antihypertensive drugs and nitro drugs. When used in combination with cytochrome P450 inhibitors such as macrolide antibiotics (such as erythromycin, clindamycin, triacetyloleandomycin, spiramycin, josamycin), azole antifungal agents (such as ketoconazole, itraconazole), protease inhibitors (such as ritonavir, indinavir) or cimetidine, the drug concentration of this product can be increased, thereby causing peripheral vasoconstriction, so it should be avoided.

Store in a dark place below 25℃. Keep out of reach of children.

1ml:0.3mg

24 months

Beijing Yimin Pharmaceutical Co., Ltd.

• Founded in:

  1981-01-31

• Address:

  North of Yongjun Road, Shunyi District, Beijing

• Tax NO.:

  91110113102531398L

• Registered Funds:

  5.18 million yuan

• Website:

  Log in to view

• Email:

  Log in to view